Loading...

PVLA PALVELLA THERAPEUTICS INC Product Launches 8-K Filing

PLVL

PVL

PALVELLA THERAPEUTICS INC

(PVLA)

2025 8-K

Earnings Announcement

Stock Offering Details

Preliminary Financials

Investor Conference Call

Positive Study Results

Corporate Presentation

Corporate Presentation Update

Study Results Announcement

Earnings Announcement

Investor Conference Call

Program Expansion

Corporate Presentation Posted

Financial Results Announced

Financial Statements

Earnings Announcement

Investor Presentation

Investor Presentation

Annual Meeting Results

Merger Announcement

Agreement with James Geraghty

Merger Agreement

Termination of Collaboratio...

Compliance Regained

Reverse Stock Split

Financial Condition

Lease Termination

Contract Cancelled

Annual Meeting Approval

Financial Results and Clini...

Discontinuation of Joint Re...

Earnings Reports

Earnings Reports

External Links:

On December 15, 2025, Palvella Therapeutics, Inc. reported positive results from its Phase 2 TOIVA study of QTORIN™ 3.9% rapamycin anhydrous gel for treating cutaneous venous malformations. This filing is significant for the company as it highlights a potential advancement in their product development.

AI Assistant

PALVELLA THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.